Literature DB >> 31463113

Video-assisted thoracoscopic surgery for invasive pulmonary fungal infection in haematology patients.

Han Ma1, Jun Wang1, Xiao Ma2, Shiying Zheng1, Haitao Ma1, Jinfeng Ge1.   

Abstract

BACKGROUND: Invasive pulmonary fungal infection in haematological patients sometimes was a difficult problem in diagnosis and treatments. This retrospective study was intended to assess the outcomes of video-assisted thoracoscopic surgery (VATS) in the treatments of this problem.
METHODS: From January 2011 to December 2017, a total of 51 haematological patients underwent VATS for invasive pulmonary fungal infection. We collected and then analyzed potential factors including general conditions, types of haematological diseases, preoperative clinical symptoms, surgical procedures, length of postoperative hospital stay, incidence of postoperative complications and postoperative follow-ups.
RESULTS: Of the 51 patients, 32 patients underwent video-assisted thoracoscopic wedge resection (62.7%), 6 patients underwent video-assisted thoracoscopic segmentectomy (11.8%) and 13 patients underwent video-assisted thoracoscopic lobectomy (25.5%). The mean operative time was 110.24±38.12 min. The average intraoperative blood loss was 112.35±87.85 mL. The mean postoperative hospital stay was 7.75±3.27 days. Prolonged air leak was found in 6 patients (11.8%), followed by excessive effusion which was found in 4 patients (7.8%). No life-threatening complications or resurgence of fungal infection occurred after surgery. Twenty-seven patients (52.9%) received postoperative antifungal therapies. No 30-day mortality and pulmonary fungal infection recurrence occurred in 6 to 24 months follow-ups.
CONCLUSIONS: VATS is an effective and safe option in management of invasive pulmonary fungal infection among patients with haematological diseases.

Entities:  

Keywords:  Video-assisted thoracoscopic surgery (VATS); haematological diseases; outcomes; pulmonary invasive fungal infection

Year:  2019        PMID: 31463113      PMCID: PMC6688021          DOI: 10.21037/jtd.2019.07.13

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  32 in total

1.  Clinical trials of antifungal prophylaxis among patients undergoing surgery.

Authors:  Thierry Calandra; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2004-10-15       Impact factor: 9.079

2.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

3.  The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients.

Authors:  Cornelia Lass-Flörl; Gudrun Resch; David Nachbaur; Astrid Mayr; Günther Gastl; Jutta Auberger; Ralf Bialek; Martin C Freund
Journal:  Clin Infect Dis       Date:  2007-08-20       Impact factor: 9.079

4.  Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia.

Authors:  Peter Matt; Franziska Bernet; James Habicht; Franco Gambazzi; Alois Gratwohl; Hans-Reinhard Zerkowski; Michael Tamm
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

5.  Pneumonectomy for complex aspergilloma: is it still dangerous?

Authors:  Yuji Shiraishi; Naoya Katsuragi; Yutsuki Nakajima; Masahiro Hashizume; Nobumasa Takahashi; Yoshikazu Miyasaka
Journal:  Eur J Cardiothorac Surg       Date:  2005-12-06       Impact factor: 4.191

6.  Resection of invasive pulmonary aspergillosis in immunocompromised patients.

Authors:  I Pidhorecky; J Urschel; T Anderson
Journal:  Ann Surg Oncol       Date:  2000-05       Impact factor: 5.344

Review 7.  How corticosteroids control inflammation: Quintiles Prize Lecture 2005.

Authors:  Peter J Barnes
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

8.  Hematopoietic stem cell transplantation in patients with active fungal infection: not a contraindication for transplantation.

Authors:  Z S Aki; G T Sucak; Z A Yeğin; O Güzel; G Erbaş; E Senol
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

9.  Adverse drug events complicate antifungal therapy for pulmonary aspergilloma.

Authors:  Amy Pakyz; Gonzalo Bearman
Journal:  Consult Pharm       Date:  2008-10

Review 10.  The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.

Authors:  Kwok M Ho; Jeffrey Lipman; Geoffrey J Dobb; Steven A R Webb
Journal:  Crit Care       Date:  2005-10-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.